ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 690

Molecular Analysis of 9G4+ Antibodies in Systemic Lupus Erythematosus

Christopher Richardson1, Asiya Seema Chida2, Erin Fox1, Lin Silver1, Diana G. Adlowitz1, Scott Jenks3, Elise Palmer1, Christopher Tipton4 and Ignacio Sanz5, 1University of Rochester, Rochester, NY, 2Medicine, Emory University Medical Center, Atlanta, GA, 3Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, 4Medicine/Rheumatology, Emory University, Atlanta, GA, 5Rheumatology, Emory University, Atlanta, GA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: antibodies and systemic lupus erythematosus (SLE), B cells

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Elevated titers of serum autoantibodies expressing the 9G4 idiotype are highly specific for SLE and correlate with disease activity and clinical manifestations.  9G4+ antibodies have been shown to be reactive to a wide variety of autoantigens, including B cells, dsDNA, and cardiolipin.  In this study we analyze the molecular characteristics that contribute to this autoreactivity.

Methods: A panel of 9G4+ monoclonal antibodies was generated from single FACS-sorted naïve (CD19+IgD+CD27-CD24+CD38+) and isotype-switched memory (CD19+IgD-CD27+) B cells from SLE patients and healthy controls.  Site-directed mutagenesis of the hydrophobic patch and light chain exchange were performed.  Monoclonal antibodies were tested by ANA, dsDNA, and cardiolipin ELISA.  Reactivity to B cells and apoptotic cells was determined by flow cytometry.  The contribution of the hydrophobic patch, the HCDR3, and light chains to binding of the various self-antigens was analyzed.

Results:   A significant percentage of 9G4+ monoclonal antibodies were reactive to autoantigen, including Hep-2 nuclear antigens (65%), B cells (48%), apoptotic cells (22%), dsDNA (9%), and cardiolipin (7%).  Strong binding to apoptotic cells, dsDNA, and cardiolipin was more common among antibodies derived from SLE memory cells.  Site-directed mutagenesis showed that B cell binding is mediated by the VH4-34-encoded FR1 hydrophobic patch (which also determines the expression of the 9G4 idiotype).  By contrast, autoreactivity to the other SLE-related antigens is patch-independent and is actually enhanced by elimination of the 9G4 idiotype.  In addition, apoptotic cell and ANA-dsDNA reactivity correlate with the charge of the HCDR3, while B cell binding does not.  Finally, light chains can substantially change VH4-34-associated autoreactivity. 

Conclusion:   Our findings show that 9G4+ antibodies are reactive to several antigens important in SLE pathogenesis, and bind antigen in two fundamentally different ways.  We also show that the intrinsic autoreactivity imprinted by the expression of 9G4+ VH4-34 heavy chains can be substantially modulated by somatic hypermutation and light chain replacement.


Disclosure:

C. Richardson,
None;

A. S. Chida,
None;

E. Fox,
None;

L. Silver,
None;

D. G. Adlowitz,
None;

S. Jenks,
None;

E. Palmer,
None;

C. Tipton,
None;

I. Sanz,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-analysis-of-9g4-antibodies-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology